Formulation and In-vitro Evaluation of Matrix Type Transdermal Patches Containing Telmisartan

Abstract

Matrix type transdermal patches of telmisartan were aimed to develop to overcome the drawbacks by oral application. Patches of telmisartan were prepared using polymers such as hydroxypropyl methylcellulose (HPMC), ethyl cellulose (EC) and Eudragit L 100 (EL 100) as film formers, dibutyl phthalate as a plasticizer and span 20 and sodium lauryl sulphate as permeation enhancers. The solvent evaporation method was employed to develop the patches using aluminum foil as the backing membrane. The prepared patches were evaluated for physicochemical properties, in vitro release and in-vitro permeation studies across shed snake skin Franz diffusion cell. On the basis of in-vitro release performance, HPMC:EL 100 in the ratio of 3:2 (TA3) was selected for incorporation of permeation enhancers. The permeation studies showed that formulation containing 5% span 20 (TD3) exhibited greatest cumulative amount of drug permeated (1771.86 mcg) in 24 h. The formulation TD3 was concluded as optimized formulation is likely to suffice the therapeutic requirement.